View : 16 Download: 0

Salvage chemotherapy for pretreated gastric cancer: A randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone

Title
Salvage chemotherapy for pretreated gastric cancer: A randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone
Authors
Kang J.H.Lee S.I.Lim D.H.Park K.-W.Oh S.Y.Kwon H.-C.Hwang I.G.Lee S.-C.Nam E.Shin D.B.Lee J.Park J.O.Park Y.S.Lim H.Y.Kang W.K.Park S.H.
Ewha Authors
남은미
SCOPUS Author ID
남은미scopus
Issue Date
2012
Journal Title
Journal of Clinical Oncology
ISSN
0732-183XJCR Link
Citation
vol. 30, no. 13, pp. 1513 - 1518
Indexed
SCI; SCIE; SCOPUS WOS scopus
Abstract
Purpose: When designing this trial, there was no evidence that salvage chemotherapy (SLC) in advanced gastric cancer (AGC) resulted in substantial prolongation of survival when compared with best supportive care (BSC). However, SLC is often offered to pretreated patients with AGC for anecdotal reasons. Patients and Methods: Patients with AGC with one or two prior chemotherapy regimens involving both fluoropyrimidines and platinum and with an Eastern Cooperative Oncology Group performance status (PS) 0 or 1 were randomly assigned in a ratio of 2:1 to SLC plus BSC or BSC alone. Choice of SLC - either docetaxel 60 mg/m2 every 3 weeks or irinotecan 150 mg/m2 every 2 weeks - was left to the discretion of investigators. Primary end point was overall survival (OS).Results: Median OS was 5.3 months among 133 patients in the SLC arm and 3.8 months among 69 patients in the BSC arm (hazard ratio, 0.657; 95% CI, 0.485 to 0.891; one-sided P = .007). OS benefit for SLC was consistent in most of the prospectively defined subgroups, including age, PS, number of prior treatments, metastatic sites, hemoglobin levels, and response to prior chemotherapy. SLC was generally well tolerated, and adverse events were similar in the SLC and BSC arms. We found no median OS difference between docetaxel and irinotecan (5.2 v 6.5 months; P = .116).Conclusion: To our knowledge, this is the largest phase III trial comparing SLC plus BSC with BSC alone in AGC. In pretreated patients, SLC is tolerated and significantly improves OS when added to BSC. © 2012 by American Society of Clinical Oncology.
DOI
10.1200/JCO.2011.39.4585
Appears in Collections:
의학전문대학원 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE